close
References
  1. Hobbs KT, Krischak M, Tejwani R, Purves JT, Wiener JS, Routh JC. The importance of early diagnosis and management of pediatric neurogenic bladder dysfunction. Res Rep Urol. 2021;13:647-657.
  2. National Spina Bifida Patient Registry, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention. About the National Spina Bifida Patient Registry. November 15, 2021. Accessed January 10, 2022. https://www.cdc.gov/ncbddd/spinabifida/nsbprregistry.html
  3. Routh JC, Cheng EY, Austin JC, et al. Design and methodological considerations of the Centers for Disease Control and Prevention Urologic and Renal Protocol for the Newborn and Young Child with Spina Bifida. J Urol. 2016;196(6):1728-1734.
  4. Stein R, Bogaert G, Dogan HS, et al. EAU/ESPU guidelines on the management of neurogenic bladder in children and adolescent part I diagnostics and conservative treatment. Neurourol Urodyn. 2020;39(1):45-57.
  5. Sager C, Barroso U Jr, Bastos JM Netto, Retamal G, Ormaechea E. Management of neurogenic bladder dysfunction in children update and recommendations on medical treatment. Int Braz J Urol. 2022;48(1):31-51.
  6. Kroll P. Pharmacotherapy for pediatric neurogenic bladder. Paediatr Drugs. 2017;19(5):463-478.
  7. Tanaka ST, Paramsothy P, Thibadeau J, et al. Baseline urinary tract imaging in infants enrolled in the UMPIRE protocol for children with spina bifida. J Urol. 2019;201(6):1193-1198.
  8. Chu DI, Liu T, Patel P, et al. Kidney function surveillance in the National Spina Bifida Patient Registry: a retrospective cohort study. J Urol. 2020;204(3):578-586.
  9. Sturm RM, Cheng EY. The management of the pediatric neurogenic bladder. Curr Bladder Dysfunct Rep. 2016;11:225-233.
  10. Tanaka ST, Yerkes EB, Routh JC, et al. Urodynamic characteristics of neurogenic bladder in newborns with myelomeningocele and refinement of the definition of bladder hostility: findings from the UMPIRE multi-center study. J Pediatr Urol. 2021;17(5):726-732.
  11. da Fonseca EG. Quality of life factors in bladder and bowel dysfunction. In: Franco I, Austin PF, Bauer SB, von Gontard A, Homsy Y, eds. Pediatric Incontinence: Evaluation and Clinical Management. John Wiley & Sons, Ltd; 2015.
  12. Ikeda H, Oyake C, Oonuki Y, et al. Complete resolution of urinary incontinence with treatment improved the health-related quality of life of children with functional daytime urinary incontinence: a prospective study. Health Qual Life Outcomes. 2020;18(1):14.
  13. Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2006;(4):CD003781.
  14. Blais AS, Bergeron M, Nadeau G, Ramsay S, Bolduc S. Anticholinergic use in children: persistence and patterns of therapy. Can Urol Assoc J. 2016;10(3-4):137-140.
  15. Ditropan (oxybutynin chloride). Prescribing information. Ortho-McNeil Pharmaceutical, Inc.; 2008.
  16. Wishahi M. Lower urinary tract dysfunction in pediatrics progress to kidney disease in adolescents: toward precision medicine in treatment. World J Nephrol. 2021;10(4):37-46.
  17. Duong V, Iwamoto A, Pennycuff J, Kudish B, Iglesia C. A systematic review of neurocognitive dysfunction with overactive bladder medications. Int Urogynecol J. 2021;32(10):2693-2702.
  18. Ghezzi E, Chan M, Kalisch Ellett LM, et al. The effects of anticholinergic medications on cognition in children: a systematic review and meta-analysis. Sci Rep. 2021;11(1):219-224.
  19. Kim SJ, Johny A, Hsieh A, et al. The effect of anticholinergic use on the neurocognitive scores of pediatric spina bifida patients. Society for Pediatric Urology (SPU) 2021 Fall Congress. December 2-5, 2021; Miami, FL. Abstract P12.
  20. Griebling TL, Campbell NL, Mangel J, et al. Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR). BMC Geriatr. 2020;20(1):109-119.
  21. US Food and Drug Administration. FDA approves new indication for drug to treat neurogenic detrusor overactivity in pediatric patients. March 25, 2021. Accessed January 10, 2022. https://www.fda.gov/news-events/press-announcements/fda-approves-new-indication-drug-treat-neurogenic-detrusor-overactivity-pediatric-patients
  22. Baka-Ostrowska M, Bolong DT, Persu C, et al. Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: an open-label, phase 3, dose-titration study. Neurourol Urodyn. 2021;40(6):1490-1499.
  23. Cooley LF, Kielb S. A review of botulinum toxin A for the treatment of neurogenic bladder. PM R. 2019;11(2):192-200.
  24. Johnson V. OnabotulinumtoxinA approved for pediatric neurogenic detrusor overactivity. February 10, 2021. Accessed January 10, 2022. https://www.neurologylive.com/view/onabotulinumtoxina-approved-pediatric-neurogenic-detrusor-overactivity
  25. Austin PF, Franco I, Dobremez E, et al. OnabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children. Neurourol Urodyn. 2021;40(1):493-501.
  26. Fischer N, Church P, Lyons J, McPherson AC. A qualitative exploration of the experiences of children with spina bifida and their parents around incontinence and social participation. Child Care Health Dev. 2015;41(6):954-962.
  27. Johnston AW, Wiener JS, Purves JT. Pediatric neurogenic bladder and bowel dysfunction: will my child ever be out of diapers? Eur Urol Focus. 2020;6(5):838-867.
  28. Liu T, Ouyang L, Thibadeau J, et al. Longitudinal study of bladder continence in patients with spina bifida in the National Spina Bifida Patient Registry. J Urol. 2018;199(3):837-843.
  29. Szymanski KM, Cain MP, Whittam B, Kaefer M, Rink RC, Misseri R. Incontinence affects health-related quality of life in children and adolescents with spina bifida. J Pediatr Urol. 2018;14(3):279.e1-279.e8.
  30. Sawin KJ, Brei TJ, Houtrow AJ. Quality of life: guidelines for the care of people with spina bifida. J Pediatr Rehabil Med. 2020;13(4):565-582.
  31. Queally JT, Barnes MA, Castillo H, Castillo J, Fletcher JM. Neuropsychological care guidelines for people with spina bifida. J Pediatr Rehabil Med. 2020;13(4):663-673.
  32. Kritikos TK, Holmbeck GN. Family functioning guidelines for the care of people with spina bifida. J Pediatr Rehabil Med. 2020;13(4):535-542.
  33. Goodley D, Runswick-Cole K. The body as disability and possibility: theorizing the ‘leaking, lacking and excessive’ bodies of disabled children. Scand J Dis Res. 2013;15(1):1-19.